IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지

Inhibition of Cell Migration by Corticotropin-Releasing Hormone (CRH) in Human Natural Killer Cell Line, NK-92MI

Corticotropin-Releasing Hormone (CRH)에 의한 인간 자연 살해 세포(NK-92MI)의 Migration 억제

  • Cheon, So-Young (Department of Life Science, Sookmyung Women's University) ;
  • Bang, Sa-Ik (Department of Plastic Surgery, Samsung Medical Center, Sunhkyunkwan University School of Medicine) ;
  • Cho, Dae-Ho (Department of Life Science, Sookmyung Women's University)
  • 천소영 (숙명여자대학교 이과대학 생명과학과 면역학실험실) ;
  • 방사익 (성균관대학교 의과대학 성형외과학교실) ;
  • 조대호 (숙명여자대학교 이과대학 생명과학과 면역학실험실)
  • Published : 2005.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Natural killer (NK) cells are CD3 (-) CD14 (-) CD56 (+) lymphocytes. They play an important role in the body's innate immune response. They can induce spontaneous killing of cancer cells or virus-infected cells via the Fas/Fas ligand or the granzyme/perforin systems. The corticotropin-releasing hormone (CRH) is an important regulator for the body's stress response. It promotes proliferation and migration of various cancer cells through the CRH type 1 receptor under stress, and also inhibits NK or T cell activity. However, the relationship of CRH and NK cell migration to the target has not been confirmed. Herein, we study the effect of CRH on NK cell migration. Methods: We used the human NK cell line, NK-92MI, and tested the expression of CRH receptor type 1 on NK-92MI by RT-PCR. This was to examine the effect of CRH on tumor and NK cell migration, thus NK cells (NK-92MI) were incubated with or without CRH and then each CRH treated cell's migration ability compared to that of the CRH untreated group. Results: We confirmed that CRH receptor type 1 is expressed in NK-92MI. CRH can decrease NK cell migration in a time-/dose-dependent manner. Conclusion: These data suggest CRH can inhibit NK cell migration to target cells.

Keywords

References

  1. Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ, Hughes TL, Marburger TB, Sung J, Baiocchi RA, Guimond M, Caligiuri MA: A human CD34(+) subset resides lymph nodes and differentiates into CD56bright natural killer cells. Immunity 22;295-304, 2005 https://doi.org/10.1016/j.immuni.2005.01.013
  2. Hamerman JA, Ogasawara K, Lanier LL: NK cells in innate immunity. Curr Opin Immunol 17;29-35, 2005 https://doi.org/10.1016/j.coi.2004.11.001
  3. Russell JH, Ley TJ: Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20;323-370, 2002 https://doi.org/10.1146/annurev.immunol.20.100201.131730
  4. Gismondi A, Jacobelli J, Strippoli R, Mainiero F, Soriani A, Cifaldi L, Piccoli M, Frati L, Santoni A: Proline-rich tyrosine kinase 2 and Rac activation by chemokine and intergrin receptors controls NK cell transendothelial migration. J Immunol 170;3065-3073, 2003 https://doi.org/10.4049/jimmunol.170.6.3065
  5. Franitza S, Grabovsky V, Wald O, Weiss I, Beider K, Dagan M, Darash-Yahana M, Nagler A, Brocke S, Galun E, Alon R, Peled A: Differential usage of VLA-4 and CXCR4 by CD3+CD56+ NKT cells and CD56+CD16+ NK cells regulates their interacton with endothelial cells. Eur J Immunol 34;1333-1341, 2004 https://doi.org/10.1002/eji.200324718
  6. Robertson MJ, Williams BT, Christopherson K 2nd, Brahmi Z, Hromas R: Regulation of human natural killer cell migration and proliferation by the exodus subfamily of CC chemokines. Cell Immunol 199;8-14, 2000 https://doi.org/10.1006/cimm.1999.1601
  7. Kim MH, Albertsson P, Xue Y, Kitson RP, Nannmark U, Goldfarb RH: Expression of matrix metalloproteinases and their inhibitor by rat NK cells: inhibition of their expression by genistein. In Vivo 14;557-564, 2000
  8. Albertsson P, Kim MH, Jonges LE, Kiston RP, Kuppen PJ, Johansson BR, Nannmark U Goldfarb RH: Matrix metal-loproteinasese of NK cells. In Vivo 14;269-276, 2000
  9. Aguilera G, Rabadan-Diehl C, Nikodemova M: Regulation of pituitary corticotropin releasing hormone receptors. Peptides 22;769-774, 2001 https://doi.org/10.1016/S0196-9781(01)00390-4
  10. Hauger RL, Irwin MR, Lorang M, Auilra G, Brown MR: High intracerebral levels of CRH result in CRH receptor down-regulation in the amygdala and neuroimmune desensitization Brain Res 616;283-292, 1993 https://doi.org/10.1016/0006-8993(93)90219-D
  11. Shibasaki T, Hotta M, Sugihara H, Wakabayashi I: Brain vasopressin is involved in stress-induced suppression of immune function in the rat. Brain Res 808;84-92, 1998 https://doi.org/10.1016/S0006-8993(98)00843-9
  12. Pedersen WA, McCullers D, Culmsee C, Haughey NJ, Herman JP, Mattson MP: Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer'disease. Neurobiol Dis 8;492-503, 2001 https://doi.org/10.1006/nbdi.2001.0395
  13. Roe SY, McGowan EM, Rothwell NJ: Evidence for the involvement of corticotrophin-releasing hormone in the pathogenesis of traumtic brain injury. Eur J Neurosci 10;553-559, 1998 https://doi.org/10.1046/j.1460-9568.1998.00064.x
  14. Cheon SY, Daeho Cho: Enhancement of cell migration by corticotropin-releasing hormoen (CRH) in human gastric cancer cell line, MKN-28. Immune Network 4;224-249, 2004 https://doi.org/10.4110/in.2004.4.4.224
  15. Ishida Y, Migita K, Izumi Y, Nakao K, Ida H, Kawakami A, Abiru S, Ishibashi H, Eguchi K, Ishii N: The role of IL-18 in the modulation of matrix metalloproteinases and migration of human natural killer (NK) cells. FEBS Lett 569;156-160, 2004 https://doi.org/10.1016/j.febslet.2004.05.039